Matthew Call
2023
In 2023, Matthew Call earned a total compensation of $2.8M as Chief Operating Officer at iTeos Therapeutics, a 2% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $209,396 |
|---|---|
| Option Awards | $1,664,000 |
| Salary | $472,850 |
| Stock Awards | $432,960 |
| Other | $23,968 |
| Total | $2,803,174 |
Call received $1.7M in option awards, accounting for 59% of the total pay in 2023.
Call also received $209.4K in non-equity incentive plan, $472.9K in salary, $433K in stock awards and $24K in other compensation.
Rankings
In 2023, Matthew Call's compensation ranked 330th out of 2,910 executives tracked by ExecPay. In other words, Call earned more than 88.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 330 out of 2,910 | 89th |
Division Manufacturing | 187 out of 1,602 | 88th |
Major group Chemicals And Allied Products | 128 out of 901 | 86th |
Industry group Drugs | 125 out of 864 | 86th |
Industry Biological Products, Except Diagnostic Substances | 43 out of 211 | 80th |
Source: SEC filing on April 25, 2024.
Call's colleagues
We found two more compensation records of executives who worked with Matthew Call at iTeos Therapeutics in 2023.